ISOFLURANE USP LIQUID

Land: Kanada

Sprache: Englisch

Quelle: Health Canada

Wirkstoff:

ISOFLURANE

Verfügbar ab:

FRESENIUS KABI CANADA LTD

ATC-Code:

N01AB06

INN (Internationale Bezeichnung):

ISOFLURANE

Dosierung:

99.9%

Darreichungsform:

LIQUID

Zusammensetzung:

ISOFLURANE 99.9%

Verabreichungsweg:

INHALATION

Einheiten im Paket:

100/250ML

Verschreibungstyp:

Prescription

Therapiebereich:

INHALATION ANESTHETICS

Produktbesonderheiten:

Active ingredient group (AIG) number: 0114368001; AHFS:

Berechtigungsstatus:

APPROVED

Berechtigungsdatum:

2006-10-05

Fachinformation

PRODUCT
MONOGRAPH
PR
ISOFLURANE USP
(Isoflurane, 99.9%)
Inhalation Anesthetic
FRESENIUS KABI CANADA LTD.
165 Galaxy Blvd, Suite 100
Toronto, ON M9W 0C8
Date of Revision:
May 23, 2018
Control No.: 215732
Isoflurane USP - Product Monograph_ _
Page 2 of 26
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT
INFORMATION.................................................................................
3
INDICATIONS AND CLINICAL USE
......................................................................................
3
CONTRAINDICATIONS
............................................................................................................
3
WARNINGS AND PRECAUTIONS
..........................................................................................
4
ADVERSE REACTIONS
............................................................................................................
8
DRUG INTERACTIONS
..........................................................................................................
11
DOSAGE AND ADMINISTRATION
......................................................................................
13
OVERDOSAGE
.........................................................................................................................
15
STORAGE AND STABILITY
..................................................................................................
17
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................... 17
PART II: SCIENTIFIC INFORMATION
...............................................................................18
PHARMACEUTICAL INFORMATION
..................................................................................
18
DETAILED PHARMACOLOGY
.............................................................................................
19
TOXICOLOGY
.................................................................................................................